ABBV

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+1.49%

Status

scored

Maintain Hold on ABBV at $272—price is within 1% of the 52-week high with RSI 67 and above the upper Bollinger Band, committing the binding 9/28 "add at resistance" pattern ahead of two binary catalysts (Q3 2026 earnings in 2-3 weeks plus the CMS IRA negotiation window with Imbruvica in active negotiation). Keep the 2.55% dividend as the income floor and stage dry powder at $250-260 (50 SMA / prior breakout zone) for tranche adds if catalysts disappoint; lift the add zone to $265-270 only after a clean Q3 beat with raised guidance AND no IRA negative headlines. The 10% notional light tail hedge is more proportionate than the conservative's 15-20% proposal for a beta-0.228 defensive compounder with a 3-7% historical earnings-reaction range.

Outcome

✓

Return

+0.39%

Status

scored

Maintain Hold on ABBV with 50-55% position sizing pre-earnings, executing a ~10% trim into $274-275 strength while establishing a protective collar (sell $275-280 call / buy $245-250 put) through the Q3 binary catalyst; hard stop remains at $258 (50 SMA) with post-earnings sizing calibrated to 60-70% on confirmed breakout, 40% on soft print if 50 SMA holds.

Outcome

✗

Return

+1.75%

Status

scored

Hold ABBV at current exposure without adding at $266.69, as the price sits at resistance with MACD histogram already negative (-0.10), volume declining ~30%, and a binary Q3 2026 earnings catalyst ahead in late October. Maintain stops at $254 and wait for either a pullback to $254-258 on >5M volume with reversal candle, or a confirmed close above $272 on >6M volume with MACD histogram turning positive.

Outcome

✓

Return

+0.35%

Status

scored

Hold ABBV at full size and do not initiate new exposure at the current $265.76 level due to resistance, negative MACD, and a binary Q3 earnings event in approximately 3 weeks; instead, trail the existing stop to $257.97 (50 SMA) and hedge the binary catalyst risk via a protective put with a $255-260 strike rather than trimming. Add 40-50% on a confirmed close above $271.35 with MACD histogram re-crossing positive and RSI >62, or add 40-50% on a pullback to $257.97 with RSI >45 and MACD re-crossing positive, with immediate reassessment following the Q3 earnings print.

Outcome

✗

Return

+1.12%

Status

scored

ABBV receives a HOLD rating with a contingent trim trigger rather than immediate action. The $16B net debt expansion and FCF erosion are already priced (PEG 0.54, 16.4x forward P/E), and the 10/01 bounce (+1.1% on 5.54M shares) validated the $257.84 50 SMA floor—the aggressive 25–33% trim would repeat the JNJ/ORCL pattern just falsified by negative alpha. Pre-committed triggers activate a 10–15% trim only on failed breakout at $266–$270, or 25–33% on structural break below $255.

Outcome

✗

Return

+1.11%

Status

scored

Maintain existing ABBV exposure at current levels; do not add at $260 given the stock sitting on 50 SMA ($257.72) with confirmed MACD bearish cross and light volume distribution not yet validated. Hard stop set at $253 (1.5 ATR below current), with Q3 2026 earnings mid-October as the binary catalyst gate warranting compressed reassessment timeline.

Outcome

✓

Return

-0.63%

Status

scored

Maintain Hold on ABBV at $261 as the binding 9/28 reflection explicitly warns against adding at the resistance zone, with the prior $263-266 Overweight call producing -0.9% alpha and validating the staged entry framework over directional conviction. The technical picture shows deteriorating momentum (MACD crossed below signal line, RSI decayed from 61.5 to 51.7, Sep 30 bearish outside-bar with elevated volume), warranting patience despite the fundamentally constructive thesis (16x forward PE, PEG 0.54, ~$16.9B FCF). Staged triggers at $253-258 (Tranche 1, 25%), $270.57 close above with volume ≥5M (Tranche 2, 50%), and $275 breakout (Tranche 3, 25%) replace the Buy entry, with $248 stop and mid-October reassessment pulled forward from Q3 earnings.

Outcome

✓

Return

-0.65%

Status

scored

Portfolio Manager ratifies a HOLD rating on ABBV, rejecting aggressive initiation at the current $263 level and instead preserving the Research Manager's Overweight thesis through a disciplined three-tranche entry framework. The binding constraint is the 9/28 ABBV reflection: bias staged entries toward the pullback tranche ($258-260) rather than adding at resistance. Q3 2026 earnings (late October) serves as the binary catalyst gate for full Overweight upgrade or Underweight downgrade, with price targets of $275 near-term, $295-305 base case, and $320+ bull case on a 12-month horizon.

Outcome

✗

Return

-1.12%

Status

scored

ABB is rated Overweight with a $280 price target and 12-month constructive horizon, warranting gradual position building through three staged tranches: 35% at $263-266, 35% on pullback to the $255-260 50 SMA zone, and 30% on confirmed breakout above $270.57 with volume exceeding 5M shares. A stop at $250 (with hard exit at $248) and protective collar through Q3 2026 earnings manage risk against the binary catalyst of Skyrizi/Rinvoq reacceleration vs. deceleration below 15% YoY.

Outcome

✓

Return

+0.73%

Status

scored

Maintain ABBV at current position without aggressive adding or trimming. The structural thesis remains intact (Skyrizi/Rinvoq growth, 2.1x net leverage, PEG 0.54, beta 0.28 defensive quality) but near-term risk/reward at $260 is unfavorable at $6 upside to $270 versus $14 downside to $250 without breakout confirmation. Q3 2026 earnings in late October serve as the binary catalyst gate for directional action.

Outcome

✓

Return

-0.29%

Status

scored

Maintain ABBV as a defensive yield anchor at reduced sizing, executing a 15-20% trim now while deploying tiered stops at $256 (50 SMA warning) and $248 (hard exit below September swing low). Re-entry requires both Q3 2026 earnings validation of the $16+ forward EPS trajectory and price confirmation above $275 on above-average volume, addressing technical distribution without abandoning the fundamental strength of ABBV's fortress balance sheet and secular Skyrizi/Rinvoq tailwinds.

Outcome

✓

Return

+0.02%

Status

scored

Maintain ABBV at Hold with a tiered scale-in plan (25% at $260-262, 25% at $256-258, 25% on $270+ breakout) and protective puts at $250 strike ahead of Q3 earnings. The $248 level serves as the thesis-defining stop, as the risk/reward from current $265 levels (10 points upside to $275 target vs. 17 points downside to $248) is unfavorable at resistance.

Outcome

✓

Return

-0.05%

Status

scored

Maintain current ABBV exposure with no new capital committed at $265; honor the trailing stop at $250.16 absolutely. Stage 1/3 of intended add size into the $257-260 confluence shelf, reserving the remaining 2/3 for either a deeper flush to $250-252 or a volume-confirmed breakout above $269.23 on ≥4.5M shares. Q3 2026 earnings in late October serves as the critical binary decision gate with quarterly FCF as the primary validation metric.

Outcome

✓

Return

+0.28%

Status

scored

Maintain ABBV at current weight with no additions above $260; implement a self-funding collar (sell $275-280 call/buy $245-250 put) through Q3 2026 earnings to hedge binary SKYRIZI/Rinvoq risk. Add triggers are either a pullback to $240 (50 SMA retest zone) or a confirmed weekly close above $270 on volume >6M shares, with hard stop at $245. Q3 earnings in late October serves as the binary decision gate for reassessment in either direction.

Outcome

–

Return

+0.20%

Status

scored

Trim 25-40% of ABBV into the $266-267 double-top resistance zone with a hard stop at $271, reducing to neutral or modestly underweight versus the pharma sector benchmark; do not initiate new longs at current levels. The Underweight call rests on three independent pillars: forward P/E of 16.2x represents a premium to all pharma peers (JNJ ~15x, MRK ~14x, PFE ~12x), the technical setup is mixed with the stock at resistance lacking momentum follow-through, and binary concentration risk in SKYRIZI + RINVOQ (70%+ of incremental growth) is unpriced at current levels. The analyst community has effectively bracketed a $245-267 trading range with the midpoint ($256) materially below the current $264, creating asymmetric risk/reward that favors trimming. Maintain 60-75% of the position to preserve upside participation while defining risk; deploy a self-funding collar for accounts retaining exposure. Q3 2026 earnings in late October is the binary inflection point requiring explicit reassessment.

Outcome

✓

Return

-0.02%

Status

scored

Maintain ABBV at 3-4% portfolio cap without initiating new longs above $260, treating this as a hold-and-carry trade to collect the 2.64% dividend while awaiting a better technical entry; scale in on weakness at $258/$254/$250 with hard stops below $245, trim 10-20% into rallies at $268-272, and sell covered calls at $270-275 (2-3 month expiry) to generate ~1-2% option premium.

Outcome

✓

Return

+0.58%

Status

scored

Maintain ABBV at current sizing with no new positions at $262; re-entry triggers are a pullback to the $250-255 zone with RSI below 45, or a confirmed weekly close above $270 on above-average volume. Hard stop sits at $232, with key monitoring points including 10Y Treasury yields above 5.2%, Skyrizi/Rinvoq growth deceleration below 5% YoY, and the October 25 Q3 earnings report.

Outcome

✓

Return

-0.20%

Status

scored

AbbVie upgraded from Hold to Overweight with 40-50% initial position sizing and staged deployment strategy; primary entry at $258 with secondary tranche at $254-256 on 50 SMA retest, scaling to 60-70% only on confirmation (breakout above $267 with volume or successful retest of 50 SMA at $254.48 with stabilization). The 14% upside to Wolfe's $300 PT and structural earnings-quality concerns (PEG reliance on amortization mean-reversion, $84.66B intangibles) prevent strong Buy conviction despite attractive valuation (forward P/E 16.2x, PEG 0.53, all-time-high $16.99B Q2'26 revenue, $16.87B FCF) and validated post-Humira transition.

Outcome

✓

Return

+0.49%

Status

scored

Maintain ABBV at $261.77 with a HOLD rating as the stock sits 37% up the Bollinger Band near 52-week highs with bearish MACD crossover, creating unfavorable risk/reward (~2.7% upside to $267 resistance vs ~5% downside to $248 lower band). Implement a self-funding collar hedge (sell $275-280 call / buy $245-250 put) ahead of Q3 earnings in late October to protect against binary event risk while preserving upside; add only on a retest of the $248-252 support zone with bullish reversal structure, and trim 10-15% only if price pushes to $265-270 with RSI rollover or MACD non-confirmation.

Outcome

✗

Return

+1.81%

Status

scored

ABBV is maintained at Hold with reduced position size of 1.5-2% versus the prior 2.5% floor, as the risk/reward is approximately symmetric at current $257 levels (96% of 52-week high) with 4% upside to $267 versus 7% downside to $240. The recommendation is to trim 5-10% on confirmed close above $260 and layer a collar/covered call overlay to hedge the binary Q3 earnings catalyst, with add zone reduced to $250-254 contingent on MACD flipping above signal or close >$258.25.

Outcome

✓

Return

+0.83%

Status

scored

Maintain ABBV at current weight with no additions above $250; staged entry starting at $246-$250 on confirmed weakness, second tranche below $243 only on confirmed close with volume; stop loss set at $243; reassess on closes at $260.50 (upside) or $246.50 (downside).

Outcome

✓

Return

+1.63%

Status

scored

ABBV is upgraded to OVERWEIGHT at 1.1x normal strategic weight with staged deployment starting at $248.50, supported by 15.4x forward P/E, PEG 0.36, and $16.87B trailing FCF against an intact structural uptrend. Position is capped at 1.1x (not 1.25x) with a hard stop at $226, hard invalidation at $245 close on above-average volume, and explicit monitoring triggers for FCF coverage, leverage, and momentum deterioration given razor-thin 1.01x Q2 2026 FCF coverage and MACD histogram at -1.50 and expanding. The 12-month price target is $275 with expected total return of 11–17%.

Outcome

✓

Return

+0.86%

Status

scored

Upgrade ABBV from Hold to Overweight with 25% Tranche 1 deployment in the $244-$247 zone (preferring lower Bollinger band test at $245.43), stop at $238 (1.5x ATR), and three-tranche staged entry based on momentum and technical confirmations. The upgrade is justified by 15.3x forward P/E with PEG 0.36, the 6.5% pullback on positive etentamig Phase 3 data, and intact long-term uptrend, while maintaining Overweight rather than Buy to respect the 9/04 binding reflection on disciplined sizing for defensive compounders with negative momentum.

Outcome

✗

Return

-2.99%

Status

scored

Maintain ABBV at 1.5–2% weight (reduced from 2.5% floor) following the 9/03 binding reflection that explicitly directs trimming toward the lower end of the size range when MACD turns negative on defensive mega-caps near 52-week highs; stop set at $249 (below 50 SMA at $254, above lower Bollinger Band at $245), with first downside trim trigger at close <$254 on >4M vol, trim trigger at $265–$267 for top-side discipline (15–20%), and hard stop at close <$224 (200 SMA) leading to Underweight reassessment. Expected payoff 2.3–5.6% over 3–6 months from dividend and modest grind, though aggressive upside ($280–290) is rejected per binding lessons.

Outcome

✗

Return

-1.44%

Status

scored

Maintain ABBV at 2.5% portfolio weight with HOLD rating; the three-analyst consensus confirms neutral positioning. Laddered entry zone is $252–$258 post-FOMC with tranches at $257 (30%), $254 (40%), and $251 (30%), stop at $248, price target $270 over 3–6 months yielding expected 2.3–5.6%.

Outcome

✓

Return

-0.58%

Status

scored

Maintain ABBV at 2.5% portfolio weight without adding at the current $261.72 price, where risk/reward is skewed unfavorably at ~1:1.5 with only 5-9% upside to the $275-285 bull case versus 8-14% downside to the $240-252 bear case. Refine the add zone from $240-244 to $252-256, as the Neutral Analyst's correction accounts for ABBV's low 0.28 beta making deeper entry points unlikely, with Q3 FCF serving as the critical confirming data point.

Outcome

✓

Return

+0.67%

Status

scored

Maintain ABBV at 2.5% weight with Hold rating; do not add at $259.99 as the 16x forward multiple prices normalized earnings and MACD has turned negative with failed breakouts at $266-267 resistance. The Aggressive Analyst's BUY thesis fails on three counts: forward multiple stretch, technical entry asymmetry, and dated catalyst mispricing. Scaled add triggers at breakout >$267.47 with volume >5M and MACD re-expansion, or pullback to $245-248 with positive MACD divergence. Trim triggers at closes below $252, $248, and $244 respectively, with hard stop at $240.

Outcome

✗

Return

+1.39%

Status

scored

Maintain ABBV at 2.5% weight (Hold rating) with a $268 price target over 3-6 months. The position respects binding prior lessons by rejecting aggressive addition at stretched multiples (8/11) and avoiding trimming that would forfeit convexity on intact structure (8/14). A $244 hard stop and time-based 10-session reassessment clause calibrate for the 8/25 circuit breaker breach (sustained -1%+ alpha vs SPY), with tighter trim triggers (close <$248) above the 50 SMA at $251.20.

Outcome

✓

Return

+0.37%

Status

scored

Maintain ABBV at 2.5% weight (floor of 2-4% range) with HOLD rating across all analysts. Do not add at current price $255.48 given freshly negative MACD histogram, price below 10 EMA, and 26% hawkish FOMC tail risk. Existing holders defend with trailing stop at $251.18; new adds require either retest of $251 with bullish reversal and MACD re-expansion, or breakout above $267 on >5M shares volume. Target $268 over 3-6 months (1.8:1 reward-to-risk ratio is symmetric, not asymmetric).

Outcome

✓

Return

-1.03%

Status

scored

ABBV maintains a HOLD rating at 2.5% weight (lower end of 2-4% range) given the binding 8/25 relative-performance circuit breaker breach (two consecutive alpha breaches at -1.1% and -2.5% vs SPY). The structural thesis remains intact (forward P/E 15.85, PEG 0.43, $16.87B FCF, golden cross preserved), but aggressive addition at ~$258 is rejected due to unfavorable technical asymmetry ($9 upside to $267 vs $8 downside to $250) and four consecutive lower highs. The position earns negative carry-adjusted alpha and must be defended by technical structure rather than fundamental narrative.

Outcome

✗

Return

-1.81%

Status

scored

Maintain ABBV at 2.5% weight (floor of 2-4% range) to collect the ~3.5% dividend as active alpha while awaiting trigger conditions; do not add at current $262.90 price due to unfavorable 1.3:1 risk/reward to $249.72 stop, and do not trim given intact structure and dividend sustainability.

Outcome

✓

Return

-1.09%

Status

scored

Maintain ABBV at 2.5% portfolio weight (lower end of 2-4% range per the 8/24 binding lesson) with Hold rating; do not add at $265.79 or trim. The position earns 2.62% dividend yield as active alpha while awaiting either an upside breakout above $269.95 with volume confirmation or a pullback into the $253-255 value zone. Downside triggers are calibrated earlier than the Conservative Analyst's $248.86 level: 10% trim on close below $259.79, additional 10-15% trim on close below $253.80, with full reassessment below the 200-SMA at $224.31.

Outcome

✓

Return

+0.48%

Status

scored

Maintain ABBV at current weight with neutral positioning: anchor sizing at 2.5-3% (middle of 2-4% range), defend the $252 closing stop giving ~2x ATR breathing room while capping downside at ~4.7%, and monitor specific triggers for conditional adds, partial trims, and reassessment to Underweight. The HOLD synthesizes a real constructive case (PEG of 0.43 on normalized earnings, 16.2x forward PE, macro tailwind from higher-for-longer rates) and a real bearish case (18% extension above 200 SMA, $3B+ operating profit concentration in immunology) where neither's strongest argument justifies action.

Outcome

✓

Return

-0.17%

Status

scored

Maintain ABBV at current weight as Hold, resisting both the Research Manager/Trader's 25-30% trim proposal and the aggressive analyst's recommendation to add. The decision is driven by binding lessons from prior 8/14 and 8/18 reflections showing that trimming defensive compounders with intact structure consistently forfeits convexity, with ABBV's current technical setup (golden cross, 18.4% above 200 SMA, RSI 64.35, fresh MACD bullish cross at +1.26) even stronger than prior Hold decisions that generated +4.1% and +2.5% alpha. Define two explicit triggers: upside add on confirmed close above $268 with >5M shares volume deploying 10-15%, and downside reassess on confirmed close below $247 (50 SMA) with rising volume moving to Underweight.

Outcome

✓

Return

+1.20%

Status

scored

Maintain ABBV at Hold with no directional commitment, adding only in 2-3% tranches (not 5%) if the $253-$255 zone prints with confluence, and trimming 10-15% tactically only on a confirmed close below $255 with expanding volume. Hard stop at $245 (50 SMA break), with Q3 2026 earnings as the next binary decision point.

Outcome

✓

Return

-1.56%

Status

scored

Maintain ABBV at its current weight without adding at $266.00, as the $265.97 close remained below the $266.60 upper Bollinger Band after a $266.92 intraday test, leaving the breakout unconfirmed. A small conditional add is acceptable only after sustained confirmation above $266.60 for 2-3 sessions with above-average volume, or on a pullback to $245-$252, with 25-30% trimming recommended into $278-$280 and a $237 core mental stop retained.

Outcome

✗

Return

+2.72%

Status

scored

ABBV is maintained at Hold with a $260 price target and 3-6 month horizon, as the 60-70% base case of sideways-to-modestly-higher drift in the $240-260 range with 2.76% dividend carry outweighs both bull and bear tails. Tactical position adjustments are disciplined: 10-15% adds are triggered only on pullbacks to $250-254 (with RSI>55 and 10 EMA hold at $251.27), while 10-15% trims occur only on exhaustion signals (close above $267 with volume below 4M shares); the $244 stop anchored to the 50 SMA replaces the noise-level $252 stop.

Outcome

✗

Return

+3.43%

Status

scored

AbbVie warrants a Hold as the base case (60-70% probability of $240-260 sideways-to-modestly-higher drift) dominates both bull and bear tails, making current weight the appropriate calibration. The aggressive analyst's PEG-of-0.41 thesis is mechanically distorted by $5.8B in trailing special charges and MACD remains negative, while the conservative's trim prescription sacrifices the 2.77% dividend carry and defensive characteristics (0.28 beta) for roughly 50bps of captured appreciation with negative expected value. The $222 stop at the 200-day SMA remains the structurally coherent risk level.

Outcome

✗

Return

+0.35%

Status

scored

Trim ABBV exposure approximately 20-25% toward neutral weight given distribution signals (price below VWMA and Bollinger middle, MACD histogram deepening to -1.01), asymmetric risk/reward (10.7% downside to 200 SMA at $222.68 versus ~6% upside to $263-265 resistance), and lack of catalyst or technical confirmation to justify holding. Re-entry requires either successful 50 SMA retest with reversal signals (RSI curling up from sub-45, MACD histogram turning positive, VWAP reclaim on expanding volume) or clean Q3 earnings with stable forward EPS revisions in the $13-14+ range.

Outcome

✓

Return

-0.54%

Status

scored

Maintain ABBV as a defensive core holding at 5–7% portfolio weight, collecting the 2.77% dividend while awaiting either a pullback to the $240–245 zone or a confirmed breakout above $263 with MACD recovery. The $242 closing-basis mental stop defines the risk boundary; partial trim 10–15% on confirmed close above $263.30 with MACD reclaiming the signal line.

Outcome

✓

Return

+0.83%

Status

scored

Maintain ABBV with a Hold rating, collecting the 2.77% dividend while awaiting Q3 2026 earnings (late October) as the next inflection point; respect the $222 hard stop on the existing position and add opportunistically at the $240–242 zone per the trader's plan, targeting $260.

Outcome

✗

Return

-0.53%

Status

scored

Initiate ABBV as Overweight at $243–247 via staged 2–3 tranche entries deploying 60–70% of moderate-conviction sizing, with a $240.50 closing stop (vs. the rejected $242.50 proposed stop) aligned to the 6.32 ATR to avoid whipsaw. Reserve the final tranche as upside optionality for a confirmation add above $251 with MACD contraction; initial targets are $275–280 with stretch to $290+ over 3–6 months.

Outcome

✓

Return

+0.85%

Status

scored

Initiate ABBV at Overweight with a staged scale-in strategy targeting $263-270 over 3-6 months; 40% initial tranche in the $244-248 zone, 35% on confirmed close above $250 with volume >5M shares, and 25% reserved for 50 SMA retest at ~$240 with positive RSI divergence. Hard stop at $220 (close below 200 SMA). The 15.25x forward P/E with 0.40 PEG ratio and >20% growth in SKYRIZI/RINVOQ support the thesis, though post-earnings MACD negativity and floating-rate debt exposure warrant the staged approach over full position deployment.

Outcome

✓

Return

+0.78%

Status

scored

Maintain ABBV with a 1-2% tactical add at current levels ($244-247) to modestly improve cost basis; hold off on larger 3-4% position increase until MACD histogram turns positive AND price reclaims VWMA at $253. The $238 hard stop remains the capital-preservation trigger, as a confirmed break opens downside to the 200 SMA at $222 (~10% from spot). Fundamentals are solid (Forward P/E 15x, PEG 0.40, Q2 non-GAAP EPS $3.65 beat) but technical fragility (price below 10-day EMA, MACD histogram -2.46 and widening) warrants disciplined position sizing. Reassess at August CPI print (8/12-13) and BOTOX masseter FDA decision.